Brexit Medicine

BREXIT and the pharma industry

Brexit is causing concerns regarding the effect it will have on the pharmaceutical industry and the supply of medicines to patients.

Our key concerns and implications for the sector are around regulation, research and development, trade, investment, and supply.


Access to the UK market could be delayed due to the loss of single marketing authorization through the EMA. Furthermore, the EMA has relocated to Amsterdam which is a ‘bitter pill to swallow’.

’Our economy will suffer. Our health sector will suffer. Our successful pharmaceutical industry will suffer.’

Rory Palmer, Labour Party Spokesperson.

Scientific research & development

The level of UK participation in future EU research and development programmes is still unclear. A no-deal Brexit could mean the loss of around £0.5bn of funding, and throw UK leadership positions and projects into disarray.

'A hard Brexit ‘could cripple UK science...’

Nobel Laureates


Increased costs and cashflow issues could arise if trade with the EU became subject to duties or import VAT.  Research by the Nuffield Trust reports that permanent product price increases for the NHS could add up to £2.3 bn in extra costs for the NHS by the end of 2019/20.


The UK may lose access to EU funds ultimately reducing funding access and venture capital investments for SMEs. This could mean the loss of €2.5bn annually from the European Structural Investment (ESI) funds, a €2m loss from the European Investment Fund (EIF) and a massive hole left from the potential loss of European Investment Bank (EIB) funding, which has contributed €117bn over its lifetime to the UK. This would also diminish the UK’s ability to attract talent and impact our research reputation.

'Medicines would be prioritised over food in the case of a no deal Brexit…’

Health Secretary, Matt Hancock.



Supply chain & operations

Regulatory changes will impact supply chains. Companies are stockpiling drugs after warnings that there could be an interruption to supplies of medications. AstraZeneca announced it would increase its stockpile of drugs by 20% to cover the Brexit transition period. Despite these contingency plans, people are still concerned about the impact on operational supply chains.

Sign up for updates

Enter your email to recieve updates from the InkLab blog.

Medical Communication Services

Inklab has extensive experience in providing bespoke and synergistic medical communications solutions with the unique added extra of its own in-house digital and instructional design team. We can quickly transform complex medical and scientific content into multiple digital formats for many different target audiences.

Talk to us today about how our medical writing team make your complex information easy to understand for different audiences.